Clinical trial · Observational
HRQOL in Locally Advanced Thyroid Carcinoma
Health-related Quality of Life of Patients With Locally Advanced Thyroid Cancer Receiving Targeted Therapy
NCT05824312CI-TRIAL-00065872LATCQOLunknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study was to explore the changes of health-related quality of life (HRQOL) in patients with locally advanced thyroid cancer (LATC) receiving TKI drugs (anlotinib, lenvatinib, etc.).
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Health Related Quality of Life | — | UNRESOLVED | — |
| Thyroid Cancer | Malignant Thyroid Gland Neoplasm | CURATED_EXACT | 0.92 |
| Tyrosine Kinase Inhibitor | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Tyrosine kinase inhibitor drugs. | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- TKI group
- description
- patients with LATC receiving Tyrosine kinase inhibitor drugs.
- interventionNames
- Drug: Tyrosine kinase inhibitor drugs.
- label
- Controlled group
- description
- patients with LATC receiving other treatment.
Primary outcomes (1)
- measure
- the global status of QLQ C30 questionnaire
- timeFrame
- 1 year
- description
- Change in global HRQOL score between baseline and at 12 months after treatment. A change of more than 10% is set as a limit for a significant change
Secondary outcomes (2)
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * Patients age (18-70 year old) * Diagnosis of locally advanced thyroid cancer * Patient receiving TKI drugs. Exclusion Criteria: * pregnancy or breastfeeding women; * history of other malignant diseases, unstable angina, myocardial infarction, cerebral infarction or cerebral hemorrhage within 6 months; (3) patients missing questionnaires greater than 3 times.
References
Publications (0)
Data not yet available
No reference posted for this study.